4.7 Article

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease EXCEL Trial

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 72, Issue 7, Pages 754-765

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.05.057

Keywords

chronic kidney disease; coronary artery bypass grafting; coronary artery disease; left main; percutaneous coronary intervention

Funding

  1. Eli Lilly/Daiichi-Sankyo
  2. Bristol-Myers Squibb
  3. AstraZeneca
  4. Medicines Company
  5. OrbusNeich
  6. Bayer
  7. CSL Behring
  8. Abbott Laboratories
  9. Watermark Research Partners
  10. Novartis Pharmaceuticals
  11. Medtronic
  12. AUM Cardiovascular
  13. Beth Israel Deaconess Medical Center
  14. Abbott
  15. Boston Scientific
  16. Biotronik
  17. Micell Technologies
  18. Medinol
  19. Abbott Vascular
  20. Edwards Lifesciences
  21. Tryton Medical Inc.
  22. Cardinal Health
  23. Cardiovascular Systems Inc.
  24. Pi-Cardia

Ask authors/readers for more resources

BACKGROUND The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronic kidney disease (CKD) remains unclear. OBJECTIVES This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal function from the multicenter randomized EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial. METHODS CKD was defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m(2) using the CKD Epidemiology Collaboration equation. Acute renal failure (ARF) was defined as a serum creatinine increase >= 5.0 mg/dl from baseline or a new requirement for dialysis. The primary composite endpoint was the composite of death, myocardial infarction (MI), or stroke at 3-year follow-up. RESULTS CKD was present in 361 of 1,869 randomized patients (19.3%) in whom baseline estimated glomerular filtration rate was available. Patients with CKD had higher 3-year rates of the primary endpoint compared with those without CKD (20.8% vs. 13.5%; hazard ratio [HR]: 1.60; 95% confidence interval [CI]: 1.22 to 2.09; p = 0.0005). ARF within 30 days occurred more commonly in patients with compared with those without CKD (5.0% vs. 0.8%; p < 0.0001), and was strongly associated with the 3-year risk of death, stroke, or MI (50.7% vs. 14.4%; HR: 4.59; 95% CI: 2.73 to 7.73; p < 0.0001). ARF occurred less commonly after revascularization with PCI compared with CABG both in patients with CKD (2.3% vs. 7.7%; HR: 0.28; 95% CI: 0.09 to 0.87) and in those without CKD (0.3% vs. 1.3%; HR: 0.20; 95% CI: 0.04 to 0.90; p(interaction) = 0.71). There were no significant differences in the rates of the primary composite endpoint after PCI and CABG in patients with CKD (23.4% vs. 18.1%; HR: 1.25; 95% CI: 0.79 to 1.98) and without CKD (13.4% vs. 13.5%; HR: 0.97; 95% CI: 0.73 to 1.27; p(interaction) = 0.38). CONCLUSIONS Patients with CKD undergoing revascularization for LMCAD in the EXCEL trial had increased rates of ARF and reduced event-free survival. ARF occurred less frequently after PCI compared with CABG. There were no significant differences between PCI and CABG in terms of death, stroke, or MI at 3 years in patients with and without CKD. (EXCEL Clinical Trial [EXCEL]; NCT01205776) (c) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available